New ALS drug tested for safety in small trial
NCT ID NCT04632225
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the safety of an experimental drug called engensis in 18 people with amyotrophic lateral sclerosis (ALS). Participants received either engensis or a placebo injection into their muscles. The main goal was to check for side effects, while also exploring effects on muscle strength, breathing, and quality of life. The study did not aim to cure ALS, but to see if the drug is safe enough for further testing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Austin Neuromuscular Center
Austin, Texas, 78759, United States
-
Hanyang University Medical Center
Seoul, 04763, South Korea
-
Johns Hopkins University Department of Neurology
Baltimore, Maryland, 21205, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
St. Joseph's Hospital and Medical Center, Barrows Neurological Institute
Phoenix, Arizona, 85013, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a brain disease change behavior years before diagnosis?
- Can a cancer drug slow ALS? a trial aims to find out
- Can conversation unlock clues to ALS speech decline?
- Could a simple Pre-Tube ritual ease feeding problems in ALS?
- Can tracking brain changes over time unlock the secrets of frontotemporal dementia?
- A muscle test in the thigh may reveal how ALS attacks the body